News Breaks |
|
|
| March 21, 2013 |
| 08:40 EDT |  | PCRX, ELN, QCOR, FRX, PFE, ENDP | Jefferies to host a summit
Specialty Pharma Summit is being held in Denver on March 21. |
|
|
News For ELN;ENDP;FRX;PCRX;PFE;QCOR From The Last 14 Days Check below for free stories on ELN;ENDP;FRX;PCRX;PFE;QCOR the last two weeks. |
|
|
| May 23, 2013 |
| 11:41 EDT |  | ELN | Elan board rejects Royalty Pharma's revised tender offer
 Subscribe for More Information |
|
| 08:10 EDT | | FRX | Forest Labs says Howard Solomon to retire as CEO, President at year end
Forest Laboratories announced that Howard Solomon will retire as Chief Executive Officer and President, effective December 31, 2013. Subject to the same nominating and election processes annually as all directors, Solomon is expected to remain as Chairman through the 2014 Annual General Meeting, at which time another Chairman will be elected. Solomon will retain the title of Chairman Emeritus after the 2014 AGM and has agreed to serve as Senior Advisor to the Company following his retirement as CEO and President. As previously disclosed, an independent committee of Forest’s Board has been engaged in a succession planning process, including evaluating internal and external candidates. With Solomon’s retirement announcement, the Board has determined to bring the process to a close and expects to name a successor before the end of the year. The committee is being assisted by executive search firm Spencer Stuart, the company said. |
|
| 08:04 EDT | | FRX | Forest Labs says Howard Solomon to retire as CEO, President at year end
Subscribe for More Information |
|
| 06:35 EDT | | ELN | Royalty Pharma lowers acceptance threshold to 50% for Elan offer
Subscribe for More Information |
|
| May 22, 2013 |
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| May 21, 2013 |
| 07:16 EDT | | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| 07:07 EDT |  | ELN | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray
Subscribe for More Information |
| |
| May 20, 2013 |
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| 13:03 EDT | | ELN | Elan advises holders to take no action related to Royalty offer
Subscribe for More Information |
|
| 11:46 EDT | | ELN | Royalty Pharma ups offer for Elan to $12.50 per share in cash
Royalty Pharma announced that it raised its takeover offer for Elan to $12.50 per share in cash. The increased offer is fully financed, cash confirmed and not conditional on due diligence, the company added, while saying the $1.00 per share net cash right has been eliminated. Royalty Pharma added that it has reserved its right to waive down the acceptance threshold for the increased offer from 90% to 50% plus one Elan share. Reference Link |
|
| 11:43 EDT | | ELN | Elan rallies 3.6% to $12.10 after Royalty Pharm raises buyout offer
|
|
| 11:42 EDT | | ELN | Royalty Pharma raises offer for Elan to $12.50 per share in cash
Subscribe for More Information |
|
| 07:28 EDT | | FRX | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| 07:27 EDT | | FRX | American Psychiatric Association to host annual meeting
Subscribe for More Information |
|
| 05:54 EDT | | ELN | Elan announces transactions to transform company, $200M share repurchase plan
Elan announces a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravance royalty participation agreement and dividend pass through announced last week and the previously completed Tysabri transaction, will form a dynamic and unique business foundation for Elan in the years ahead. Elan will acquire 100% of AOP Orphan Pharmaceuticals and upon close Elan will pay EUR 263.5M for the company, comprised of EUR 175.7M in cash and EUR 87.8M of Elan ordinary shares. In addition, there will be potential cash milestone payments of up to EUR 270M on the advancement of certain late stage clinical programs. Elan has completed the first step in its investment in Newbridge by paying $40M in exchange for 48% of the total fully diluted capitalization of the company. In addition, Elan has appointed two directors to the board of Newbridge. Elan has the option to purchase the remaining stake in Newbridge by 2015 for a sum of $244M. Elan will commit $70M to the new entity upfront, plus up to a potential future $8M, for an 18% minority equity position, royalties in major markets along with additional milestones, and retention of commercial rights in certain territories and markets. The third party equity financial partner will commit $20M for 62% equity position, plus up to a potential future $2M. The remaining 20% equity will be allocated among Speranza management. This allows Elan to eliminate the operating activities associated with the development of the drug, while at the same time maintaining a share of the potential upside. A $200M share repurchse program is planned, details pending. |
|
| 05:22 EDT | | ELN | Elan to host business news update conference call
Subscribe for More Information |
|
| May 17, 2013 |
| 11:53 EDT |  | ENDP | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
Subscribe for More Information |
| |
|
|
|
|
